Radiosensitivity

radiotherapy tolerance tests

SHORT VERSION

Radiosensitivity defines the sensitivity level of each patient to the radiation used in radiation therapy.

More precisely, radiosensitivity defines the sensitivity level of a cell, organ, tissue, or tumor to irradiation: the part of cells, tissue or tumor that will die in response to irradiation. 

Each patient and each tumor will react differently to the same dose of radiotherapy. This individual sensitivity is related to genetic variations among individuals and among tumors. 

Some environmental factors also can influence the radiosensitivity of tissues. For example, smoking increases the sensitivity of healthy tissues to radiation, and consequently also the risk of toxicity.

[Radiotherapy hair loss

Notez cet post

FIRST TESTS TO PREDICT A PATIENT’S RADIOSENSITIVITY

NovaGray develops and commercializes the first radiotherapy tolerance tests for patients treated for breast or prostate cancer.

Performed before the start of radiotherapy with a simple blood draw, the tests assess the patients’ individual radiosensitivity and determine their risk of developing late complications after radiotherapy.

WHY DO A RADIOSENSITIVITY TEST?

Knowing a patient’s individual radiosensitivity is important information that can help:

  • Reassure the patient in preparation for radiotherapy
  • Guide physicians in choosing the most appropriate treatment plan
  • Adapt patient follow-up after radiotherapy

Team NovaGray

NovaGray develops radiotherapy tolerance tests for breast and prostate cancer patients. NovaGray's mission is to help personalize cancer treatment by assessing each patient's individual sensitivity before starting radiotherapy. NovaGray technology has been validated by multi-center prospective clinical trials. NovaGray tests are recommended by the French Society of Radiation Oncology (SFRO).